ES2369320T3 - Compuestos de ftalazina y pirido(3,4-d)piridazina como antagonistas del receptor h1. - Google Patents

Compuestos de ftalazina y pirido(3,4-d)piridazina como antagonistas del receptor h1. Download PDF

Info

Publication number
ES2369320T3
ES2369320T3 ES08805231T ES08805231T ES2369320T3 ES 2369320 T3 ES2369320 T3 ES 2369320T3 ES 08805231 T ES08805231 T ES 08805231T ES 08805231 T ES08805231 T ES 08805231T ES 2369320 T3 ES2369320 T3 ES 2369320T3
Authority
ES
Spain
Prior art keywords
methyl
chlorophenyl
formula
pyrrolidinyl
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08805231T
Other languages
English (en)
Spanish (es)
Inventor
Paul Martin Gore
Brian Edgar Looker
Panayiotis Alexandrou Procopiou
Sadie Vile
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ES2369320T3 publication Critical patent/ES2369320T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES08805231T 2007-10-11 2008-10-10 Compuestos de ftalazina y pirido(3,4-d)piridazina como antagonistas del receptor h1. Active ES2369320T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97910507P 2007-10-11 2007-10-11
US979105P 2007-10-11

Publications (1)

Publication Number Publication Date
ES2369320T3 true ES2369320T3 (es) 2011-11-29

Family

ID=40104668

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08805231T Active ES2369320T3 (es) 2007-10-11 2008-10-10 Compuestos de ftalazina y pirido(3,4-d)piridazina como antagonistas del receptor h1.

Country Status (6)

Country Link
US (1) US20100216799A1 (enExample)
EP (1) EP2215082B1 (enExample)
JP (1) JP2011500537A (enExample)
AT (1) ATE525370T1 (enExample)
ES (1) ES2369320T3 (enExample)
WO (1) WO2009047336A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006115221A1 (ja) * 2005-04-21 2006-11-02 Nippon Shinyaku Co., Ltd. フタラジノン誘導体及びその医薬
MX347085B (es) * 2006-12-28 2017-04-06 Abbott Laboratories * Inhibidores de la poli (adp-ribosa) polimerasa.
CA2685219C (en) * 2007-05-04 2012-06-19 Amgen Inc. Diazaquinolones that inhibit prolyl hydroxylase activity
PH12022551513A1 (en) * 2019-12-20 2023-04-24 Mirati Therapeutics Inc Sos1 inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3813384A (en) * 1972-01-17 1974-05-28 Asta Werke Ag Chem Fab Basically substituted benzyl phthalazone derivatives,acid salts thereof and process for the production thereof
PH23995A (en) * 1984-01-09 1990-02-09 Janssen Pharmaceutica Nv 4((bicycle heterocyclyl)-methyl and hetero)piperidines
ATE49205T1 (de) * 1984-09-14 1990-01-15 Asta Pharma Ag Substituierte benzylphthalazinon-derivate.
DE3677322D1 (de) * 1985-11-11 1991-03-07 Asta Pharma Ag 4-benzyl-1-(2h)-phthalazinon-derivate.
DE3634942A1 (de) * 1985-11-11 1987-05-14 Asta Werke Ag Chem Fab Neue 4-benzyl-1-(2h)-phthalazinon-derivate
EP0289939A1 (de) * 1987-05-08 1988-11-09 ASTA Pharma AG Neue 4-Benzyl-1-(2H)-phthalazinon-Derivate mit einem Aminosäurerest
CZ199593A3 (en) * 1992-10-02 1994-04-13 Asta Medica Ag Phthalazinone derivatives exhibiting anti-arrhythmic and analgesic activity and eliminating resistance to a plurality of medicaments (mdr)
DE69912379T2 (de) * 1998-08-14 2004-05-06 Pfizer Inc. Antithrombosemittel
US6180629B1 (en) * 1998-08-14 2001-01-30 Cell Pathways, Inc. [4,5]-Fused-1,3-disubstituted-1,2-diazine-6-one derivatives with nitrogen containing substitutents in position one for the treatment of neoplasia
US20030073692A1 (en) * 2001-08-07 2003-04-17 Pharmacia & Upjohn S.P.A. Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
WO2004082682A1 (en) * 2003-03-18 2004-09-30 Merck & Co. Inc. Amino cyclobutylamide modulators of chemokine receptor activity
US7595316B2 (en) * 2003-06-27 2009-09-29 Banyu Pharmaceutical Co., Ltd. Heteroaryloxy nitrogenous saturated heterocyclic derivative
WO2008074803A2 (en) * 2006-12-20 2008-06-26 Glaxo Group Limited 4-benzyl-l ( 2h) -phthalazinones as h1 receptor antagonists

Also Published As

Publication number Publication date
US20100216799A1 (en) 2010-08-26
ATE525370T1 (de) 2011-10-15
EP2215082B1 (en) 2011-09-21
JP2011500537A (ja) 2011-01-06
EP2215082A1 (en) 2010-08-11
WO2009047336A1 (en) 2009-04-16

Similar Documents

Publication Publication Date Title
US7884114B2 (en) Compounds
US20080039444A1 (en) Compounds
ES2341813T3 (es) 4-bencil-1 (2h)-ftalazinonas como antagonistas del receptor h1.
ES2641483T3 (es) Derivados piridinil- y piperazinil-metiloxi-arílicos útiles como inhibidores de tirosina quinasa de bazo (SYK)
JP2007500187A (ja) キノリン誘導体および治療におけるその使用
ES2339400T3 (es) Antagonistas del receptor de histamina que comprenden un nucleo de azepina.
EP2215082B1 (en) Phthalazine and pyrido[3,4-d]pyridazine compounds as h1 receptor antagonists
ES2337187T3 (es) Acido 3-(4-((4-(4-((3-(3,3-dimetil-1-piperidinil)propil(oxi)fenil)-1-piperidinilcarbonil)-1-naftalenil) propanoico o propenoico como antagonistas de receptor h1 y h3 para el tratamiento de trastornos inflamatorios y/o alergicos.
ES2330472T3 (es) Compuestos.
JP2009512669A (ja) Iv型ホスホジエステラーゼ(pde4)の阻害剤としてのシンノリン化合物
ES2354180T3 (es) Derivados de 4-bencilftalazinona 2-sistituidos como antagonistas de las histaminas h1 y h3.
US20100222349A1 (en) Quinoline derivatives used to treat inflammatory and allergic diseases
ES2358299T3 (es) Compuestos pirrolo[2,3-b]piridin-4-il-bencenosulfonamida como inhibidores de ikk2.
CN101472899A (zh) 用作组胺h1和h3拮抗剂的2-取代的4-苄基酞嗪酮衍生物
WO2010094643A1 (en) Quinoline derivatives and their uses for rhinitis and urticaria
WO2012025473A1 (en) Cc.chemokine receptor 4 antagonists